$INNMF Amplia Therapeutics CEO Dr. Christopher Burns joined Zacks SCR at the OTC Markets Life Sciences Virtual Investor Forum for a CEO Chat. Read the transcript: https://scr.zacks.com/news/news-detai...

HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s...

Amplia Therapeutics has pointed to new preclinical data showing its pancreatic cancer drug candidate narmafotinib can hit several drivers of the intractable disease.

Watch the presentations from three ASX-listed biotechs at the forefront of promising new cancer therapies, each advancing treatments for diseases with significant unmet medical need. Inquiries: [email protected] The session includes company updates, pipeline progress and outlook discussions from: ✅ 03:00 Racura Oncology (ASX: RAC) Racura is a Phase 3 clinical-stage company advancing RC220 across three active oncology programs. RC220 has been discovered to silence MYC — a target implicated in 70% of all cancers and long considered undruggable — via DNA G4 binding. Active programs include a Phase 3 AML trial, the HARNESS-1 Phase 1 trial in EGFR-mutant NSCLC combining RC220 with Tagrisso®, and the CPACS-1 cardioprotection trial with patients already dosed in Hong Kong and Australia. First patient dosed in both Phase 3 AML and HARNESS-1 are targeted in 2026, with HARNESS-1 carrying explicit potential for FDA Accelerated Approval. Website: https://www.racuraoncology.com/ ✅ 25:44 Amplia Therapeutics (ASX: ATX | OTCQB: INNMF) Amplia is a clinical-stage Australian biotech developing best-in-class FAK inhibitors for fibrotic cancers. Its lead drug narmafotinib has delivered 5 confirmed complete responses in advanced pancreatic cancer — a 7.8% complete response rate confirmed by independent central review, compared to 0.2% for chemotherapy alone, and never before seen in this indication. The ACCENT trial achieved a 36% objective response rate and median overall survival of 11.1 months. A registration-enabling Phase 2b study is now underway, designed in alignment with FDA feedback, with a new ovarian cancer trial (PRROSE) and kRAS inhibitor partnering discussions further expanding the pipeline. Website: https://www.ampliatx.com ✅ 47:45 Prescient Therapeutics (ASX: PTX) Prescient is developing the world's only GGTase-1 inhibitor in clinical development — a first-in-class targeted therapy advancing through Phase 2a in Cutaneous T-Cell Lymphoma (CTCL), a blood cancer with no satisfactory treatment options. Phase 1b results in CTCL delivered a 43% response rate, 100% clinical benefit rate, 12.4-month duration of response, and zero serious treatment-related adverse events. The Phase 2a trial has enrolled 18 patients across 12 active sites in Australia, the US and Italy, scaling toward 16 sites globally. GGTase-1 biology is implicated in approximately 22% of all cancers, with the CTCL market forecast at ~US$1.2bn annually by 2034. Website: https://www.ptxtherapeutics.com

HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by AmpliaApplication expands Amplia’s intellectual...

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to...

Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board...

Allele-specific KRAS inhibitors such as the KRASG12C inhibitors sotorasib and adagrasib have demonstrated clinical activity as monotherapy but adaptive signaling in response to KRAS pathway inhibition...

While many cancer companies spend billions trying to make stronger chemotherapies, Melbourne-based Amplia Therapeutics (ASX: ATX) is taking a different path, developing a “shield-breaking” treatment t...

Amplia Therapeutics has launched a pivotal registration-enabling trial of narmafotinib for pancreatic cancer, testing better efficacy with daily dosing.

FAK tyrosine kinase drives ovarian cancer tumor progression in part via effects on the tumor microenvironment. Chen et al. show that ovarian tumor FAK inhibition triggers release of omega-3 fatty acid...

We're verifying your browser

Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)

The Victorian government has made a $75 million investment through Breakthrough Victoria into five venture capital funds, aimed at boosting private capital, supporting early-stage companies and accele...

Nature Biomedical Engineering - Myeloid-specific mechanotransduction ablation downregulates pro-fibrotic fibroblast transcriptional profiles to reduce scar formation in human cells

Read and interact with this announcement: Amplia Therapeutics to Significantly Expand U.S. Presence on Amplia's investor hub